<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of polycystic ovary syndrome in adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of polycystic ovary syndrome in adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of polycystic ovary syndrome in adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Natalie Shaw, MD, MMSc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Rosenfield, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elise DeVore Berlan, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mitchell E Geffner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 08, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polycystic ovary syndrome (PCOS) should be considered in any adolescent girl with a chief complaint of hirsutism or menstrual irregularity. Acanthosis nigricans, treatment-resistant acne, scalp hair loss, or hyperhidrosis may alternatively be the chief complaint, although these features are not always present. Obesity is a common co-complaint. PCOS is diagnosed in adolescents with otherwise unexplained persistent hyperandrogenic anovulatory symptoms that are inappropriate for age and stage of adolescence [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5852.html" rel="external">
          "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         The diagnosis of PCOS has lifelong implications, with increased risk for infertility, metabolic syndrome, type 2 diabetes mellitus, cardiovascular events, and endometrial carcinoma [
         <a href="#rid2">
          2-7
         </a>
         ].
        </p>
        <p>
         Treatment for PCOS in adolescents is directed at the major clinical manifestations, which are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal uterine bleeding – Oligo-amenorrhea or excessive bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous hyperandrogenism – Primarily hirsutism and persistent acne
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity and insulin resistance
        </p>
        <p>
        </p>
        <p>
         Several treatment options have been developed for each of these in adults, and some options address more than one symptom [
         <a href="#rid1">
          1,3,8,9
         </a>
         ]. Few clinical trials focus on treatment of PCOS in adolescents. Recommendations for the management of PCOS in adolescents were presented by two international expert groups representing diverse professional stakeholder organizations in 2017 and 2018 [
         <a href="#rid10">
          10-13
         </a>
         ]. Strategies for managing PCOS and associated symptoms in adolescents are discussed in this topic review.
        </p>
        <p>
         Other aspects of PCOS in adolescents are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5852.html" rel="external">
          "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">
          "Diagnostic evaluation of polycystic ovary syndrome in adolescents"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5799.html" rel="external">
          "Etiology and pathophysiology of polycystic ovary syndrome in adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3779042043">
         <span class="h1">
          MANAGEMENT OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of therapy for PCOS depends upon the individual adolescent's clinical presentation and their goals and preferences [
         <a href="#rid11">
          11
         </a>
         ]. If possible, treatment is initiated only after evaluating for PCOS  (
         <a class="graphic graphic_algorithm graphicRef117557" href="/z/d/graphic/117557.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1,14
         </a>
         ]. Persistent hyperandrogenemia and anovulation are required to confirm the diagnosis of PCOS; however, in some cases, the symptoms are sufficiently severe (eg, excessive uterine bleeding) to require prompt empiric treatment with combined oral contraceptive pills (COCs) before persistent hyperandrogenic anovulation can be documented. Because this treatment masks hyperandrogenemia and anovulatory symptoms, pretreatment diagnostic screening should be initiated to the extent possible. In this way, a provisional diagnosis of PCOS can be made. (See
         <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">
          "Diagnostic evaluation of polycystic ovary syndrome in adolescents"
         </a>
         .)
        </p>
        <p>
         After the patient reaches gynecologic maturity, the diagnosis of PCOS can be confirmed by demonstrating hyperandrogenic menstrual abnormality during a trial off COC treatment for at least three months [
         <a href="#rid11">
          11,15
         </a>
         ].
        </p>
        <p>
         If a trial off of COC is attempted, it should be coupled with contraceptive counseling because the infertility of PCOS is relative, not absolute.
        </p>
        <p>
         Goals of treatment include addressing each of the following major symptoms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abnormal uterine bleeding –
         </strong>
         First-line treatment for PCOS is ordinarily estrogen-progestin COCs since these treat both menstrual abnormalities and hyperandrogenemia  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid9">
          9,11,16,17
         </a>
         ]. Anovulatory symptoms manifest as oligo-amenorrhea and/or excessive menstrual bleeding. The thresholds for defining these abnormal uterine bleeding patterns in adolescents are discussed separately  (
         <a class="graphic graphic_table graphicRef93199" href="/z/d/graphic/93199.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5852.html" rel="external">
          "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Anovulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oligo-amenorrhea –
         </strong>
         Oligo-amenorrhea should be treated in adolescents with PCOS, not only for psychosocial reasons, but because chronic anovulation increases the risk of developing endometrial hyperplasia, which is associated with endometrial carcinoma. Progestin is the critical ingredient in COCs that inhibits endometrial proliferation; it prevents the hyperplasia that results from unopposed estrogen action. (See
         <a class="medical medical_review" href="/z/d/html/3217.html" rel="external">
          "Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">
          "Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Excessive menstrual bleeding –
         </strong>
         Excessive menstrual bleeding due to ovulatory dysfunction is a common manifestation of PCOS and often is the initial presenting complaint  (
         <a class="graphic graphic_table graphicRef93199" href="/z/d/graphic/93199.html" rel="external">
          table 2
         </a>
         ). If the bleeding puts the patient at risk for anemia, higher doses of estrogen are sometimes needed. Heavy uterine bleeding can cause severe anemia requiring hospital admission. COCs or progestin-only regimens are usually effective in managing this symptom. However, transfusion, antifibrinolytic, or invasive treatment occasionally may be required [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5852.html" rel="external">
          "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Anovulation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117.html" rel="external">
          "Abnormal uterine bleeding in adolescents: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Prior to initiation of a COC, side effects and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=5853" target="_blank">
          risks
         </a>
         should be discussed, including the small but increased risk of venous thromboembolism (VTE)  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ). For most patients with PCOS, the benefits of COCs outweigh the potential risks of VTE. A detailed discussion of the risks and side effects of COCs is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Although PCOS is a risk factor for thromboembolism in adults [
         <a href="#rid19">
          19
         </a>
         ], VTE is rare in adolescents (1 per 4000 patient-years of contraceptive use or 3.3 per 1000 hospital discharges)
         <strong>
         </strong>
         [
         <a href="#rid20">
          20,21
         </a>
         ]. Risk factors include a family history of VTE, a history of migraine headaches with aura, obesity, smoking, autoimmune disease, immobilization, or hospitalization for surgery or infection [
         <a href="#rid22">
          22-24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         While progestin-only treatments may be used to control menstrual irregularity, they are generally less effective in PCOS than COCs because they do not reduce serum free testosterone as well as COCs do, and the androgen excess of PCOS interferes with progesterone-mediated slowing of the gonadotropin-releasing hormone pulse generator [
         <a href="#rid25">
          25,26
         </a>
         ]. The side effects and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=5853" target="_blank">
          risks
         </a>
         of progestin-only methods are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)", section on 'Counseling points'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Weight changes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cutaneous hyperandrogenism
         </strong>
         – Over one-half of adolescents with PCOS have hirsutism or moderate-to-severe acne vulgaris. Medical endocrine therapy improves these manifestations, decreasing the effect of excess androgens by:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reducing androgen production
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reducing serum free androgen levels
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Blocking androgen action at the level of target organs (eg, hair follicle)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         COCs also treat hyperandrogenemia, accomplishing the first two of these goals  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid16">
          16,17
         </a>
         ]. They lower serum free testosterone levels by decreasing ovarian production of total testosterone and by increasing serum sex hormone-binding globulin levels. They also modestly lower dehydroepiandrosterone sulfate (DHEAS) levels. Reducing androgen levels hinders the further transformation of vellus to terminal hairs, which occurs with androgen exposure. In most patients with PCOS, treatment with COCs can be expected to arrest progression of hirsutism, reduce the need for shaving by approximately one-half, and improve acne within three months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Antiandrogenic therapy, which inhibits binding of androgen to its receptor, is indicated for patients with hirsutism that does not respond sufficiently to COC treatment or for patients who are on progestin-only contraception [
         <a href="#rid16">
          16
         </a>
         ]. If this is not successful, direct hair removal is the next step.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acne
         </strong>
         –
         <strong>
         </strong>
         The treatment of acne in patients with PCOS is the same as in patients without PCOS and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/42.html" rel="external">
          "Acne vulgaris: Overview of management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adolescents with acne resistant to topical treatments should be evaluated for androgen excess before the initiation of hormonal treatment [
         <a href="#rid1">
          1
         </a>
         ]. Hyperandrogenemia would, in most cases, be due to PCOS and be an indication for COC treatment. Patients with refractory acne may also benefit from antiandrogens. (See
         <a class="local">
          'Hirsutism without abnormal uterine bleeding'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obesity and insulin resistance
         </strong>
         –
         <strong>
         </strong>
         Obesity aggravates the insulin resistance and menstrual dysfunction of PCOS. Approved treatments that reduce insulin resistance improve ovulation moderately and hyperandrogenemia slightly. Diet and exercise are first-line treatment to address obesity in adolescents with PCOS [
         <a href="#rid10">
          10,27
         </a>
         ]. If the abnormal glucose tolerance cannot be normalized by lifestyle modification, the addition of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         may be helpful. Glucagon-like peptide 1 agonists that are markedly superior to medications previously available for the induction of weight loss are approved for the treatment of adolescent obesity. These hold promise for the management of the obesity in PCOS. (See
         <a class="local">
          'Treatment of obesity and insulin resistance'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H686220589">
         <span class="h1">
          TREATMENT OF ABNORMAL UTERINE BLEEDING AND HIRSUTISM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Combination oral contraceptives
         <strong>
         </strong>
         (COCs), which contain estrogen and progestin, are usually the first-line treatment for adolescents with PCOS associated abnormal menstrual bleeding and/or cutaneous signs of androgen excess  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid8">
          8,9,16
         </a>
         ]. The estrogen-progestin combination suppresses the hypothalamic-pituitary-ovarian axis and reduces excess androgen production by the ovary, which improves menstrual regularity and decreases anovulatory uterine bleeding, hirsutism, and acne. The progestin component also inhibits gonadotropin secretion. This prevents endometrial proliferation, preventing hyperplasia and the associated risk of carcinoma.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         alone may be considered if the main objective is menstrual cycle regulation, although evidence of efficacy is limited [
         <a href="#rid9">
          9
         </a>
         ]. Rarely, alternative interventions such as gonadotropin-releasing hormone agonist therapy or glucocorticoid therapy are used instead of COCs or progestin-only plus antiandrogen treatment. This should be done in collaboration with an endocrinologist.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Abnormal uterine bleeding
         </span>
        </p>
        <p class="headingAnchor" id="H900337332">
         <span class="h3">
          Oligo-amenorrhea with hirsutism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach in patients who have oligo-amenorrhea with hirsutism depends upon whether the patient has any
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=5853" target="_blank">
          estrogen contraindications
         </a>
         . These contraindications are rare in the absence of a family history of venous thromboembolism (VTE), a history of migraine headaches with aura, or obesity associated with the comorbidities discussed above. A complete list of contraindications is discussed separately. (See
         <a class="local">
          'Management overview'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Contraindications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Eligibility'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Estrogen not contraindicated
         </strong>
         –
         <strong>
         </strong>
         In these patients, we use a combined estrogen-progestin method such as a combination oral contraceptive (COC)  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ); however, a combined estrogen-progestin contraceptive vaginal ring or transdermal patch are acceptable alternatives. Our choice is in line with International and Endocrine Society guidelines that suggest COCs as first-line pharmacologic therapy for menstrual irregularity [
         <a href="#rid8">
          8,9,11
         </a>
         ] and hirsutism [
         <a href="#rid11">
          11,16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We suggest selecting a COC that contains 30 to 35 mcg of ethinyl estradiol because COCs containing ≤20 mcg may be less effective in controlling irregular menstrual bleeding, particularly in obese hyperandrogenic adolescents, and may limit bone accrual  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid28">
          28,29
         </a>
         ]. All COCs are effective for treating hirsutism and acne [
         <a href="#rid16">
          16,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In our experience, menstrual abnormalities are usually well controlled within one to two months of starting COC treatment. COC therapy will normalize androgen levels within 18 to 21 days. We suggest rechecking serum free testosterone in the third week of COC treatment (note that an unchanged or increased total testosterone level can be misleading due to the expected elevation of sex hormone-binding globulin [SHBG] caused by estrogen). Other experts do not recheck androgen levels [
         <a href="#rid9">
          9
         </a>
         ]. Due to escape from ovarian suppression during the pill-free interval, occasional patients require an extended-cycle COC to control severe hyperandrogenemia [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If treatment is not successful in reducing androgen levels, the patient's PCOS either has an unusually prominent component of functional adrenal hyperandrogenism or the diagnosis of PCOS should be questioned. For such patients, we suggest referral to an endocrinologist for further evaluation. (See
         <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">
          "Diagnostic evaluation of polycystic ovary syndrome in adolescents", section on 'Further evaluation by endocrinology subspecialists for rare disorders mimicking PCOS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the patient's hirsutism does not improve, we suggest the addition of an antiandrogen, such as
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ). Spironolactone in combination with a COC substantially reduces hirsutism (on average the score is reduced by one-third)  (
         <a class="graphic graphic_figure graphicRef66629" href="/z/d/graphic/66629.html" rel="external">
          figure 1
         </a>
         ), although there is considerable individual variation [
         <a href="#rid32">
          32
         </a>
         ]. The decision to add an antiandrogen to a COC depends on the severity of the hirsutism and considerations of efficacy, side effects, and costs. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Estrogen contraindicated
         </strong>
         – In these patients, we treat with a progestin-only contraceptive to prevent endometrial hyperplasia and an antiandrogen to treat hirsutism  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ). Unlike COCs, oral progestins have no therapeutic effect on hirsutism; therefore, these patients will likely need the addition of an antiandrogen, such as
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         . Because antiandrogens have the potential to feminize a male fetus, the progestin-only contraceptive provides the added benefit of reducing the likelihood of an unintended pregnancy while the patient is taking a teratogenic agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Any progestin-only contraceptive can be prescribed; however, the
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          levonorgestrel intrauterine device
         </a>
         (IUD) and the
         <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">
          etonogestrel implant
         </a>
         have the advantage of providing long-acting reversible contraception. (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Available antiandrogens include the following  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          Spironolactone
         </a>
         – We generally prescribe spironolactone, the most widely used antiandrogen for this purpose, because it is safer than
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          flutamide
         </a>
         and cyproterone and probably more effective than
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          finasteride
         </a>
         [
         <a href="#rid16">
          16,33,34
         </a>
         ]. The randomized controlled trials and meta-analyses demonstrating the benefit of spironolactone are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Antiandrogens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Guidelines suggest that a dose at the upper end of the therapeutic range (ie, 100 to 200 mg given in two divided doses daily) is required to treat hirsutism; however, we suggest starting at a dose of 25 to 50 mg daily and titrating upward as tolerated and based on patient response [
         <a href="#rid16">
          16
         </a>
         ]. Approximately 9 to 12 months of therapy is required to achieve the maximal effect because of the long growth cycles of sexual hair follicles. After one year of therapy, the dose can be reduced gradually for maintenance therapy. We suggest halving the dose and re-evaluating for change every six months.
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          Spironolactone
         </a>
         must be administered as long as the patient wishes to maintain improvement in hirsutism, and 100 mg daily is probably the minimally effective dose for maintenance.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          Spironolactone
         </a>
         is usually well tolerated at these doses, but fatigue and hyperkalemia rarely limit its usefulness in some patients. Laboratory testing for electrolytes and creatinine should be performed two to four weeks after initiation of spironolactone therapy to determine whether the spironolactone dose should be lowered.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Second-line antiandrogens – Second-line antiandrogens include
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          finasteride
         </a>
         ,
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          flutamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">
          cyproterone acetate
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          Finasteride
         </a>
         – Finasteride interferes with androgen action by competitively inhibiting 5 alpha-reductase type 1, which converts testosterone to its active form, dihydrotestosterone. Finasteride was slightly less effective than
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         in some studies on the treatment of patients with hirsutism. However, meta-analysis of the limited available data has not shown a significant difference in efficacy between these treatments [
         <a href="#rid16">
          16
         </a>
         ]. The usual dose is 2.5 to 5 mg daily but can be increased to 7.5 mg.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">
          Cyproterone acetate
         </a>
         – Cyproterone acetate is a progestin with antiandrogenic activity that is sometimes used for the treatment of hirsutism. It is not available in the United States but is available in Canada and Mexico as a COC containing ethinyl estradiol and low-dose cyproterone acetate (5 mg; Diane [brand name]). It also is available in Europe in this form and as a high-dose (50 mg) progestin tablet that is combined with any form of estrogen. Drug regulatory agencies in Europe have recommended limiting its use to "second-line" therapy because of a perceived increase in risk of hepatotoxicity compared with other available progestins [
         <a href="#rid35">
          35,36
         </a>
         ]. In addition, high-dose cyproterone acetate is associated with a small increase in the risk of meningioma and is contraindicated in people with a history of meningioma. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Suggested drug: spironolactone'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">
          "Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'High-dose cyproterone'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          Flutamide
         </a>
         – Flutamide is another competitive inhibitor of androgen-receptor action. Its use has been limited by expense and the rare risk of fatal hepatocellular toxicity [
         <a href="#rid37">
          37
         </a>
         ]. Flutamide may permit ovulation in patients with PCOS; however, its utility for patients who wish to conceive is limited by the potential risk of feminization of the male fetus. The Endocrine Society hirsutism guidelines recommend against the routine use of flutamide because of its potential hepatotoxicity, expense, and the availability of other effective antiandrogens [
         <a href="#rid16">
          16
         </a>
         ]. While it has been argued that low-dose flutamide is safe [
         <a href="#rid38">
          38
         </a>
         ], the population studied is too small to be certain. There is less experience with newer, more potent and selective antiandrogens [
         <a href="#rid39">
          39,40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A more detailed discussion of these antiandrogens in the treatment of hirsutism is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Antiandrogens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         If the patient's hirsutism persists, the patient's PCOS either has an unusually prominent component of functional adrenal hyperandrogenism or the diagnosis of PCOS should be questioned. For such patients, we suggest referral to an endocrinologist for further evaluation. (See
         <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">
          "Diagnostic evaluation of polycystic ovary syndrome in adolescents", section on 'Further evaluation by endocrinology subspecialists for rare disorders mimicking PCOS'
         </a>
         .)
        </p>
        <p>
         The optimal duration of treatment has not been determined. Whereas PCOS ordinarily persists, little is known about the natural history of PCOS diagnosed in adolescence, particularly in mild cases. We advise continuing treatment until the patient is gynecologically mature (five years following menarche) or has lost a substantial amount of excess weight if obesity is a coexisting condition. We then consider a trial off of treatment for a few months. If the patient does not resume a normal menstrual cycle, restarting treatment is appropriate. If a trial off of hormonal contraception is attempted, it should be coupled with contraceptive counseling because the infertility of PCOS is relative, not absolute.
        </p>
        <p class="headingAnchor" id="H3221701072">
         <span class="h3">
          Oligo-amenorrhea without hirsutism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach in patients who have oligo-amenorrhea without hirsutism is based upon whether the patient desires contraception and whether the patient has any estrogen contraindications. The primary goal for treatment of this group is to prevent endometrial hyperplasia, which can lead to endometrial carcinoma.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraception needed
         </strong>
         – Patients who have
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=5853" target="_blank">
          contraindications
         </a>
         to estrogen are limited to progestin-only methods, while patients without estrogen contraindications may choose any hormonal method. These contraindications are rare in the absence of a family history of VTE, a history of migraine headaches with aura, or obesity associated with the comorbidities discussed above. A complete list of contraindications is discussed separately. (See
         <a class="local">
          'Management overview'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Contraindications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Eligibility'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Estrogen not contraindicated
         </strong>
         –
         <strong>
         </strong>
         In these patients, we use a combined estrogen-progestin method such as a COC  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ); however, a combined estrogen-progestin contraceptive vaginal ring or transdermal patch are acceptable alternatives. Our choice is in line with International and Endocrine Society guidelines that suggest COCs as first-line pharmacologic therapy for menstrual irregularity [
         <a href="#rid8">
          8,9,11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We suggest selecting a COC that contains 30 or 35 mcg of ethinyl estradiol because COCs containing ≤20 mcg ethinyl estradiol may be less effective in controlling irregular menstrual bleeding, particularly in obese hyperandrogenic girls, and may limit bone accrual  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Estrogen contraindicated
         </strong>
         – In these patients, we treat with a progestin-only contraceptive to prevent endometrial hyperplasia  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ). Any progestin-only contraceptive can be prescribed; however, the
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          levonorgestrel IUD
         </a>
         and the
         <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">
          etonogestrel implant
         </a>
         have the advantage of providing long-acting reversible contraception. (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraception not needed
         </strong>
         – Even when contraception is not needed, a COC is still recommended as a first-line treatment to control endometrial cycling. An alternative is to prescribe a progestin-only pill for the first 7 to 10 days of each month or of every other month  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ). Treatment with cyclic oral progestins relies on their direct inhibitory effects on endometrial proliferation. Withdrawal bleeding can be expected to occur within a few days of the last progestin dose. Although these patients may prefer to have long intervals between their menses, it is essential that they have a withdrawal bleed at least every two months to prevent endometrial hyperplasia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients must be informed that oral progestin prescribed to regulate menstrual cyclicity (ie, 7 to 10 days each month)
         <strong>
          is not
         </strong>
         a means of contraception.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          Medroxyprogesterone acetate
         </a>
         (Provera [brand name]; 10 mg given orally at bedtime to reduce nausea)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          Norethindrone
         </a>
         acetate (Aygestin [brand name]; 2.5 to 10 mg given orally daily)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Micronized
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         (Prometrium [brand name]; 100 to 200 mg given orally at bedtime to reduce nausea)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cyclic progestin therapy on an every-other-month cycle can also permit the detection of an emerging normal menstrual cycle. The optimal duration of treatment has not been determined. Whereas PCOS ordinarily persists, little is known about the natural history of PCOS diagnosed in adolescence, particularly in mild cases. We advise continuing treatment until the patient is gynecologically mature (five years following menarche) or has lost a substantial amount of excess weight if obesity is a coexisting condition. We then consider a trial off of treatment for a few months. If the patient does not resume a normal menstrual cycle, restarting treatment is appropriate. If a trial off of hormonal contraception is attempted, it should be coupled with contraceptive counseling because the infertility of PCOS is relative, not absolute.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         alone is another option if the main objective is menstrual cycle regulation, although evidence is limited [
         <a href="#rid9">
          9
         </a>
         ]. In two small trials that compared metformin with lifestyle counseling for three to six months in adolescents with PCOS, metformin increased the likelihood of menses, although the effect was not statistically significant in one of the trials [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         starting dose is 500 mg daily and is gradually increased by 500 mg per week as tolerated, to a maximum dose of 1000 to 2000 mg daily. Metformin should be taken with the evening meal to minimize nausea, which is the cause of an approximately 15 percent discontinuation rate. Higher doses are often better tolerated when divided into two daily doses or when given in an extended-release form [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1295175103">
         <span class="h3">
          Excessive bleeding with hirsutism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach in patients who have excessive bleeding with hirsutism depends upon whether the patient has any
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=5853" target="_blank">
          estrogen contraindications
         </a>
         . These contraindications are rare in the absence of a family history of VTE, a history of migraine headaches with aura, or obesity associated with the comorbidities discussed above. A complete list of contraindications is discussed separately. (See
         <a class="local">
          'Management overview'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Contraindications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Eligibility'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Estrogen not contraindicated
         </strong>
         – In these patients, we use a combined estrogen-progestin method such as a combined COC  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ). Although a combined estrogen-progestin contraceptive vaginal ring or transdermal patch are acceptable alternatives, the estrogen doses required to treat acute, excessive abnormal uterine bleeding may be three- to fourfold higher than the doses needed to treat oligo-amenorrhea. Management of acute excessive uterine bleeding is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/117.html" rel="external">
          "Abnormal uterine bleeding in adolescents: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After control is achieved, maintenance should be attempted at a lower estrogen dose because higher doses of estrogen increase the risk of VTE, particularly in patients who are overweight or obese [
         <a href="#rid44">
          44
         </a>
         ]. We suggest selecting a COC that contains 30 or 35 mcg of ethinyl estradiol because COCs containing ≤20 mcg ethinyl estradiol may be less effective in controlling heavy menstrual bleeding, particularly in obese hyperandrogenic adolescents, and may limit bone accrual  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ). All COCs are effective for treating hirsutism and acne [
         <a href="#rid16">
          16,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In our experience, menstrual abnormalities are usually well controlled within one to two months of starting COC treatment. COC therapy will normalize androgen levels within 18 to 21 days. We suggest rechecking serum free testosterone late in the third week of COC treatment (note that an unchanged or increased total testosterone level can be misleading due to the elevation of SHBG by estrogen). Other experts do not recheck androgen levels [
         <a href="#rid9">
          9
         </a>
         ]. Due to escape from ovarian suppression during the pill-free interval, occasional patients require an extended-cycle COC to control severe hyperandrogenemia [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If treatment is not successful in reducing androgen levels, the patient's PCOS either has an unusually prominent component of functional adrenal hyperandrogenism or the diagnosis of PCOS should be questioned. For such patients, we suggest referral to an endocrinologist for further evaluation. (See
         <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">
          "Diagnostic evaluation of polycystic ovary syndrome in adolescents", section on 'Further evaluation by endocrinology subspecialists for rare disorders mimicking PCOS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the patient's hirsutism does not improve, we suggest the addition of an antiandrogen, such as
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ). Spironolactone in combination with a COC substantially reduces hirsutism (on average the score is reduced by one-third)  (
         <a class="graphic graphic_figure graphicRef66629" href="/z/d/graphic/66629.html" rel="external">
          figure 1
         </a>
         ), although there is considerable individual variation [
         <a href="#rid32">
          32
         </a>
         ]. The decision to add an antiandrogen to a COC depends on the severity of the hirsutism and considerations of efficacy, side effects, and costs. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Estrogen contraindicated
         </strong>
         – For patients with acute heavy bleeding and estrogen contraindications, several progestin-only regimens are available  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ). Among the available oral progestin-only alternatives, we typically use
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         acetate because it is a potent menstrual-suppressive agent. However, since it is partially metabolized to ethinyl estradiol, a history of VTE is a contraindication to its use. Dosing and tapering regimens for norethindrone acetate are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/117.html" rel="external">
          "Abnormal uterine bleeding in adolescents: Management", section on 'Progestin-only pills'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Once the acute bleeding has been controlled, any progestin-only contraceptive can be prescribed; however, the 52 mg
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          levonorgestrel IUD
         </a>
         is not only approved for treatment of heavy menstrual bleeding, but it also, like the
         <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">
          etonogestrel implant
         </a>
         , has the advantage of providing long-acting reversible contraception. (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Unlike COCs, progestin-only methods have no therapeutic effect on hirsutism; therefore, these patients will likely need the addition of an antiandrogen, such as
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         . Because antiandrogens have the potential to feminize a male fetus, progestin-only contraceptives provide the added benefit of reducing the likelihood of an unintended pregnancy while the patient is taking a teratogenic agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Available antiandrogens include the following  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          Spironolactone
         </a>
         – We generally prescribe spironolactone, the most widely used antiandrogen for this purpose, because it is safer than
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          flutamide
         </a>
         and cyproterone and probably more effective than
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          finasteride
         </a>
         [
         <a href="#rid16">
          16,34
         </a>
         ]. The randomized controlled trials and meta-analysis demonstrating the benefit of spironolactone are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Antiandrogens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Guidelines suggest that a dose at the upper end of the therapeutic range (ie, 100 to 200 mg given in two divided doses daily) is required to treat hirsutism; however, we suggest starting at a dose of 25 to 50 mg daily and titrating upward as tolerated and based on patient response [
         <a href="#rid16">
          16
         </a>
         ]. Approximately 9 to 12 months of therapy is required to achieve the maximal effect because of the long growth cycles of sexual hair follicles. After one year of therapy, the dose can be reduced gradually for maintenance therapy. We suggest halving the dose and re-evaluating for change every six months.
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          Spironolactone
         </a>
         must be administered as long as the patient wishes to maintain improvement in hirsutism, and 100 mg daily is probably the minimally effective dose for maintenance.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          Spironolactone
         </a>
         is usually well tolerated at these doses, but fatigue and hyperkalemia rarely limit its usefulness in some patients. Laboratory testing of electrolytes and creatinine should be performed two to four weeks after initiation of spironolactone therapy to determine whether the spironolactone dose should be lowered.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Second-line antiandrogens – Second-line antiandrogens include
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          finasteride
         </a>
         ,
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          flutamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">
          cyproterone acetate
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          Finasteride
         </a>
         – Finasteride interferes with androgen action by competitively inhibiting 5 alpha-reductase type 1, which converts testosterone to its active form, dihydrotestosterone. Finasteride was slightly less effective than
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         in some studies on the treatment of patients with hirsutism. However, meta-analysis of the limited available data has not shown a significant difference in efficacy between these treatments [
         <a href="#rid16">
          16
         </a>
         ]. The usual dose is 2.5 to 5 mg daily but can be increased to 7.5 mg.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">
          Cyproterone acetate
         </a>
         – Cyproterone acetate is a progestin with antiandrogenic activity that is sometimes used for the treatment of hirsutism. It is not available in the United States but is available in Canada and Mexico as a COC containing ethinyl estradiol and low-dose cyproterone acetate (5 mg; Diane [brand name]). It also is available in Europe in this form and as a high-dose (50 mg) progestin tablet that is combined with any form of estrogen. Drug regulatory agencies in Europe have recommended limiting its use to "second-line" therapy because of a perceived increase in risk of hepatotoxicity compared with other available progestins [
         <a href="#rid35">
          35,36
         </a>
         ]. In addition, high-dose cyproterone acetate is associated with a small increase in the risk of meningioma and is contraindicated in people with a history of meningioma. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Suggested drug: spironolactone'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">
          "Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'High-dose cyproterone'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          Flutamide
         </a>
         – Flutamide is another competitive inhibitor of androgen-receptor action. Its use has been limited by expense and the rare risk of fatal hepatocellular toxicity [
         <a href="#rid37">
          37
         </a>
         ]. Flutamide may permit ovulation in patients with PCOS; however, its utility for patients who wish to conceive is limited by the potential risk of feminization of the male fetus. The Endocrine Society hirsutism guidelines recommend against the routine use of flutamide because of its potential hepatotoxicity, expense, and the availability of other effective antiandrogens [
         <a href="#rid16">
          16
         </a>
         ]. While it has been argued that low-dose flutamide is safe [
         <a href="#rid38">
          38
         </a>
         ], the population studied is too small to be certain. There is less experience with newer, more potent and selective antiandrogens [
         <a href="#rid39">
          39,40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A more detailed discussion of these antiandrogens in the treatment of hirsutism is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Antiandrogens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         If the patient's hirsutism persists, the patient's PCOS either has an unusually prominent component of functional adrenal hyperandrogenism or the diagnosis of PCOS should be questioned. For such patients, we suggest referral to an endocrinologist for further evaluation. (See
         <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">
          "Diagnostic evaluation of polycystic ovary syndrome in adolescents", section on 'Further evaluation by endocrinology subspecialists for rare disorders mimicking PCOS'
         </a>
         .)
        </p>
        <p>
         Gynecologic referral is indicated for patients who have uncontrollable abnormal bleeding despite COC therapy or whose bleeding cannot be controlled medically.
        </p>
        <p>
         The optimal duration of treatment has not been determined. Whereas PCOS ordinarily persists, little is known about the natural history of PCOS diagnosed in adolescence, particularly in mild cases. We advise continuing treatment until the patient is gynecologically mature (five years following menarche) or has lost a substantial amount of excess weight if obesity is a coexisting condition. We then consider a trial off of treatment for a few months. If the patient does not resume a normal menstrual cycle, restarting treatment is appropriate. If a trial off of hormonal contraception is attempted, it should be coupled with contraceptive counseling because the infertility of PCOS is relative, not absolute.
        </p>
        <p class="headingAnchor" id="H1284465101">
         <span class="h3">
          Excessive bleeding without hirsutism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach in patients who have excessive bleeding without hirsutism depends upon whether the patient has any
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=5853" target="_blank">
          estrogen contraindications
         </a>
         . These contraindications are rare in the absence of a family history of VTE, a history of migraine headaches with aura, or obesity associated with the comorbidities discussed above. A complete list of contraindications is discussed separately. (See
         <a class="local">
          'Management overview'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Contraindications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Eligibility'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Estrogen not contraindicated
         </strong>
         –
         <strong>
         </strong>
         In these patients, we use a combined estrogen-progestin method such as a combined COC  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ). Although a combined estrogen-progestin contraceptive vaginal ring or transdermal patch are acceptable alternatives, the estrogen doses required to treat acute, excessive abnormal uterine bleeding may be three- to fourfold higher than the doses needed to treat oligo-amenorrhea. (See
         <a class="medical medical_review" href="/z/d/html/117.html" rel="external">
          "Abnormal uterine bleeding in adolescents: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After control is achieved, maintenance should be attempted at a lower estrogen dose because higher doses of estrogen increase the risk of VTE, particularly in patients who are overweight or obese [
         <a href="#rid44">
          44
         </a>
         ]. We suggest selecting a COC that contains 30 to 35 mcg of ethinyl estradiol because COCs containing ≤20 mcg ethinyl estradiol may be less effective in controlling heavy menstrual bleeding, particularly in obese hyperandrogenic adolescents  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Estrogen contraindicated
         </strong>
         – For patients with acute heavy bleeding and estrogen contraindications, several progestin-only regimens are available  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ). Among the available oral progestin-only alternatives, we typically use
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         acetate because it is a potent menstrual suppressive agent. However, since it is partially metabolized to ethinyl estradiol, a history of VTE is a contraindication to use. Dosing and tapering regimens for norethindrone acetate are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/117.html" rel="external">
          "Abnormal uterine bleeding in adolescents: Management", section on 'Progestin-only pills'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Once the acute bleeding has been controlled, any progestin-only contraceptive can be prescribed; however, the 52 mg
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          levonorgestrel IUD
         </a>
         is not only approved for treatment of heavy menstrual bleeding, but it also, like the
         <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">
          etonogestrel implant
         </a>
         , has the advantage of providing long-acting reversible contraception. (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         alone is another option if the main objective is to maintain menstrual cycle regulation, although evidence is limited [
         <a href="#rid9">
          9
         </a>
         ]. In two small trials that compared metformin with lifestyle counseling for three to six months in adolescents with PCOS, metformin increased the likelihood of menses, although the effect was not statistically significant in one of the trials [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         starting dose is 500 mg daily and is gradually increased by 500 mg per week, as tolerated, to a maximum dose of 1000 to 2000 mg daily. Metformin should be taken with the evening meal to minimize nausea, which is the cause of an approximately 15 percent discontinuation rate. Higher doses are often better tolerated when divided into two daily doses or when given in an extended-release form [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Gynecologic referral is indicated for patients who have uncontrollable abnormal bleeding despite COC therapy or whose bleeding cannot be controlled medically.
        </p>
        <p>
         The optimal duration of treatment has not been determined. Whereas PCOS ordinarily persists, little is known about the natural history of PCOS diagnosed in adolescence, particularly in mild cases. We advise continuing treatment until the patient is gynecologically mature (five years following menarche) or has lost a substantial amount of excess weight if obesity is a coexisting condition. We then consider a trial off of treatment for a few months. If the patient does not resume a normal menstrual cycle, restarting treatment is appropriate. If a trial off of hormonal contraception is attempted, it should be coupled with contraceptive counseling because the infertility of PCOS is relative, not absolute.
        </p>
        <p class="headingAnchor" id="H2338806595">
         <span class="h2">
          Hirsutism without abnormal uterine bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach in patients who have hirsutism depends upon whether the patient has any
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=5853" target="_blank">
          estrogen contraindications
         </a>
         . These contraindications are rare in the absence of a family history of VTE, a history of migraine headaches with aura, or obesity associated with the comorbidities discussed above. A complete list of contraindications is discussed separately. (See
         <a class="local">
          'Management overview'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Contraindications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Eligibility'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Estrogen not contraindicated
         </strong>
         –
         <strong>
         </strong>
         In these patients, we use a combined estrogen-progestin method such as a COC  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ); however, the combined estrogen-progestin contraceptive vaginal ring or transdermal patch are acceptable alternatives. Although all hormonal treatment for hirsutism is off-label in the United States [
         <a href="#rid16">
          16,45
         </a>
         ], our choice is in line with International and Endocrine Society guidelines that suggest COCs as first-line pharmacologic therapy for hirsutism [
         <a href="#rid9">
          9,11,16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We suggest selecting a COC that contains 30 to 35 mcg of ethinyl estradiol because COCs containing ≤20 mcg ethinyl estradiol may limit bone accrual  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ). All COCs are effective for treating hirsutism [
         <a href="#rid16">
          16,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In our experience, COC therapy will normalize androgen levels within 18 to 21 days. We suggest rechecking serum free testosterone late in the third week of COC treatment (note that an unchanged or increased total testosterone level can be misleading due to the elevation of SHBG by estrogen). Other experts do not recheck androgen levels [
         <a href="#rid9">
          9
         </a>
         ]. Due to escape from ovarian suppression during the pill-free interval, occasional patients require an extended-cycle COC to control severe hyperandrogenemia [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If treatment is not successful in reducing androgen levels, the patient's PCOS either has an unusually prominent component of functional adrenal hyperandrogenism or the diagnosis of PCOS should be questioned. For such patients, we suggest referral to an endocrinologist for further evaluation. (See
         <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">
          "Diagnostic evaluation of polycystic ovary syndrome in adolescents", section on 'Further evaluation by endocrinology subspecialists for rare disorders mimicking PCOS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the patient's hirsutism does not improve, we suggest the addition of an antiandrogen, such as
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ). Spironolactone in combination with a COC substantially reduces hirsutism (on average the score is reduced by one-third)  (
         <a class="graphic graphic_figure graphicRef66629" href="/z/d/graphic/66629.html" rel="external">
          figure 1
         </a>
         ), although there is considerable individual variation [
         <a href="#rid32">
          32
         </a>
         ]. The decision to add an antiandrogen to a COC depends on the severity of the hirsutism and considerations of efficacy, side effects, and costs. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Estrogen contraindicated
         </strong>
         – In these patients, we treat with an antiandrogen such as
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ). Because antiandrogens have the potential to feminize a male fetus, a progestin-only contraceptive should be added to reduce the likelihood of an unintended pregnancy while the patient is taking a teratogenic agent  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Any progestin-only contraceptive can be prescribed; however, the
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          levonorgestrel IUD
         </a>
         and the
         <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">
          etonogestrel implant
         </a>
         have the advantage of providing long-acting reversible contraception. (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Available antiandrogens include the following  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          Spironolactone
         </a>
         – We generally prescribe spironolactone, the most widely used antiandrogen for this purpose, because it is safer than
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          flutamide
         </a>
         and cyproterone and probably more effective than
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          finasteride
         </a>
         [
         <a href="#rid16">
          16,34
         </a>
         ]. The randomized controlled trials and meta-analysis demonstrating the benefit of spironolactone are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Antiandrogens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Guidelines suggest that a dose at the upper end of the therapeutic range (ie, 100 to 200 mg given in two divided doses daily) is required to treat hirsutism; however, we recommend starting at a lower dose of 25 to 50 mg daily and titrating upward as tolerated and based on patient response [
         <a href="#rid16">
          16
         </a>
         ]. Approximately 9 to 12 months of therapy is required to achieve the maximal effect because of the long growth cycles of sexual hair follicles. After one year of therapy, the dose can be reduced gradually for maintenance therapy. We suggest halving the dose and re-evaluating for change every six months.
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          Spironolactone
         </a>
         must be administered as long as the patient wishes to maintain improvement in hirsutism, and 100 mg daily is probably the minimally effective dose for maintenance.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          Spironolactone
         </a>
         is usually well tolerated at these doses, but fatigue and hyperkalemia rarely limit its usefulness in some patients. Laboratory testing of electrolytes and creatinine should be performed two to four weeks after initiation of spironolactone therapy to determine whether the spironolactone dose should be lowered.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Second-line antiandrogens – Second-line antiandrogens include
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          finasteride
         </a>
         ,
         <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">
          cyproterone acetate
         </a>
         , and
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          flutamide
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          Finasteride
         </a>
         – Finasteride interferes with androgen action by competitively inhibiting 5 alpha-reductase type 1, which converts testosterone to its active form, dihydrotestosterone. Finasteride was slightly less effective than
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         in some studies on the treatment of patients with hirsutism. However, meta-analysis of the limited available data has not shown a significant difference in efficacy between these treatments [
         <a href="#rid16">
          16
         </a>
         ]. The usual dose is 2.5 to 5 mg daily but can be increased to 7.5 mg.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">
          Cyproterone acetate
         </a>
         – Cyproterone acetate is a progestin with antiandrogenic activity that is sometimes used for the treatment of hirsutism. It is not available in the United States but is available in Canada and Mexico as a COC containing ethinyl estradiol and low-dose cyproterone acetate (5 mg; Diane [brand name]). It also is available in Europe in this form and as a high-dose (50 mg) progestin tablet that is combined with any form of estrogen. Drug regulatory agencies in Europe have recommended limiting its use to "second-line" therapy because of a perceived increase in risk of hepatotoxicity compared with other available progestins [
         <a href="#rid35">
          35,36
         </a>
         ]. In addition, high-dose cyproterone acetate is associated with a small increase in the risk of meningioma and is contraindicated in people with a history of meningioma. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Suggested drug: spironolactone'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">
          "Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'High-dose cyproterone'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          Flutamide
         </a>
         – Flutamide is another competitive inhibitor of androgen receptor action. Its use has been limited by expense and the rare risk of fatal hepatocellular toxicity [
         <a href="#rid37">
          37
         </a>
         ]. Flutamide may permit ovulation in patients with PCOS; however, its utility for patients who wish to conceive is limited by the potential risk of feminization of the male fetus. The Endocrine Society hirsutism guidelines recommend against the routine use of flutamide because of its potential hepatotoxicity, expense, and the availability of other effective antiandrogens [
         <a href="#rid16">
          16
         </a>
         ]. While it has been argued that low-dose flutamide is safe [
         <a href="#rid38">
          38
         </a>
         ], the population studied is too small to be certain. There is less experience with newer, more potent and selective antiandrogens [
         <a href="#rid39">
          39,40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A more detailed discussion of these antiandrogens in the treatment of hirsutism is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Antiandrogens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         If the patient's hirsutism persists, the patient's PCOS either has an unusually prominent component of functional adrenal hyperandrogenism or the diagnosis of PCOS should be questioned. For such patients, we suggest referral to an endocrinologist for further evaluation. (See
         <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">
          "Diagnostic evaluation of polycystic ovary syndrome in adolescents", section on 'Further evaluation by endocrinology subspecialists for rare disorders mimicking PCOS'
         </a>
         .)
        </p>
        <p>
         If hirsutism is not controlled satisfactorily within six months, then direct hair removal measures can be added [
         <a href="#rid17">
          17
         </a>
         ]. The costs of these treatments are not covered by third-party payers. The decision among these options depends upon patient preference, including cost of the measure, tolerance of discomfort/pain, risk of complications, and outcome. The 2018 Endocrine Society clinical guidelines for the treatment of hirsutism suggest supplementing antiandrogen therapy with direct hair removal therapy if necessary in hyperandrogenic women, such as those with PCOS [
         <a href="#rid16">
          16
         </a>
         ]. More detailed discussions and options for direct hair removal are found separately. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Antiandrogens'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1589.html" rel="external">
          "Removal of unwanted hair", section on 'Temporary methods'
         </a>
         .)
        </p>
        <p>
         The natural history of PCOS (ie, untreated) is a slow decrease of androgens over the reproductive lifespan. Consequently, hirsutism is unlikely to resolve, and some form of ongoing therapy is needed to minimize hair growth.
        </p>
        <p class="headingAnchor" id="H3282673510">
         <span class="h1">
          TREATMENT OF OBESITY AND INSULIN RESISTANCE
         </span>
        </p>
        <p class="headingAnchor" id="H3257530231">
         <span class="h2">
          Obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         For overweight and obese patients with PCOS, weight management is a major treatment goal [
         <a href="#rid10">
          10,27
         </a>
         ]. Healthy lifestyle interventions are essential and often require attention to psychosocial and behavioral factors [
         <a href="#rid10">
          10,12
         </a>
         ]. Nevertheless, substantial and sustained improvements in weight or glycemic control are difficult to achieve, even when a lifestyle intervention program with family involvement is undertaken [
         <a href="#rid27">
          27
         </a>
         ] or when
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         is combined with behavior modification [
         <a href="#rid41">
          41,46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15848.html" rel="external">
          "Prevention and management of childhood obesity in the primary care setting"
         </a>
         .)
        </p>
        <p>
         As with the treatment of any individual with obesity, there seems to be no advantage to a low glycemic index or low-carbohydrate diet over a low-fat diet [
         <a href="#rid47">
          47,48
         </a>
         ]; rather, a reduction of both carbohydrate and fat intake in the context of a high-quality diet of natural foods is indicated [
         <a href="#rid27">
          27,49
         </a>
         ]. Patients with obesity typically experience improvement in their anovulatory symptoms roughly in proportion to the amount of weight lost [
         <a href="#rid47">
          47
         </a>
         ]. Improvement in hyperandrogenism is minimal, however [
         <a href="#rid16">
          16,48
         </a>
         ].
        </p>
        <p>
         Bariatric surgery is indicated for adolescent patients with body mass index (BMI) ≥35 or 120 percent of the 95
         <sup>
          th
         </sup>
         percentile for age and sex with comorbid conditions and BMI ≥40 or 140 percent of the 95
         <sup>
          th
         </sup>
         percentile for age and sex without comorbid conditions and access to centers that specialize in bariatric surgery in this age group for patients who have failed medical therapy [
         <a href="#rid27">
          27,50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5382.html" rel="external">
          "Obesity in adults: Behavioral therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5379.html" rel="external">
          "Obesity in adults: Role of physical activity and exercise"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5375.html" rel="external">
          "Obesity in adults: Dietary therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5880.html" rel="external">
          "Surgical management of severe obesity in adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Impaired glucose tolerance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PCOS, obesity, and impaired glucose tolerance who have not responded to diet and exercise may benefit from adjunctive treatment with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         [
         <a href="#rid11">
          11,51,52
         </a>
         ] or glucagon-like peptide 1 (GLP-1) receptor agonists. There are several methods to assess for impaired glucose tolerance. A hemoglobin A1c result of 5.7 to 6.5 percent or a two-hour blood glucose result of 140 to 199 mg/dL on an oral glucose tolerance test is diagnostic of impaired glucose tolerance. In patients with PCOS and impaired glucose tolerance, we suggest treatment with metformin.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         <strong>
          –
         </strong>
         Metformin is an insulin sensitizer with many additional actions; however, treatment of impaired glucose tolerance is an off-label use. Type 2 diabetes is the only indication for which metformin is approved by the US Food and Drug Administration. Metformin primarily lowers insulin levels by reducing hepatic glucose production [
         <a href="#rid53">
          53-57
         </a>
         ]. It also promotes ovulation and lowers androgen levels modestly (by approximately 20 percent) [
         <a href="#rid42">
          42,58-60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5799.html" rel="external">
          "Etiology and pathophysiology of polycystic ovary syndrome in adolescents", section on 'Insulin-resistant hyperinsulinism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         dose and monitoring – The metformin starting dose is 500 mg daily. It should be taken with the evening meal to minimize nausea, which is the cause of an approximately 15 percent discontinuation rate. The dose is gradually increased by 500 mg per week, as tolerated, to a maximum dose of 1000 to 2000 mg daily. Higher doses are often better tolerated when divided into two daily doses or when given in an extended-release form [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We suggest obtaining a comprehensive metabolic panel at baseline because of the rare complication of lactic acidosis [
         <a href="#rid37">
          37
         </a>
         ].
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         is contraindicated in patients with impaired hepatic or renal function, alcoholism, or cardiopulmonary insufficiency because it can cause lactic acidosis in these settings.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinical effectiveness –
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         is minimally effective for PCOS in the absence of weight control [
         <a href="#rid61">
          61
         </a>
         ]; variability in weight control may explain the inconsistent effects of metformin treatment on insulin levels [
         <a href="#rid42">
          42,62,63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7411.html" rel="external">
          "Metformin for treatment of the polycystic ovary syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Promising therapies
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         GLP-1 receptor agonists – GLP-1 receptor agonists are approved for the treatment of obesity (
         <a class="drug drug_general" data-topicid="115980" href="/z/d/drug information/115980.html" rel="external">
          semaglutide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">
          liraglutide
         </a>
         ) or type 2 diabetes (liraglutide,
         <a class="drug drug_general" data-topicid="9005" href="/z/d/drug information/9005.html" rel="external">
          exenatide
         </a>
         ) in adolescents.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The most effective of these agents,
         <a class="drug drug_general" data-topicid="115980" href="/z/d/drug information/115980.html" rel="external">
          semaglutide
         </a>
         , holds potential for the treatment of impaired glucose tolerance; however, this is an off-label use and may not be covered by insurance. This agent may be best used in collaboration with a pediatric endocrinologist. (See
         <a class="medical medical_review" href="/z/d/html/15848.html" rel="external">
          "Prevention and management of childhood obesity in the primary care setting", section on 'Pharmacotherapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5821.html" rel="external">
          "Management of type 2 diabetes mellitus in children and adolescents", section on 'Trials of GLP-1 agonists'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myo-inositol – Some dieticians recommend myo-inositol, a dietary supplement, for the treatment of obesity and/or impaired glucose tolerance. The dose is 2 g twice daily for eight weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Myo-inositol appears to be safe. In the one trial of women with PCOS, myo-inositol improved ovulatory frequency by approximately twofold compared with placebo [
         <a href="#rid64">
          64,65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1694491269">
         <span class="h1">
          OTHER RESOURCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following online resources are available to patients with PCOS and their families:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fyoungwomenshealth.org%2Fwp-content%2Fuploads%2F2014%2F10%2FPCOS-Resources-for-a-Healthier-You.pdf&amp;token=kVJoG6A%2Fde0zKYaVurhJoOl%2F3cPgXTif9uMUhUxGGvpMLnYG7P7hpO8y66v0xFO7dhEb9ARbvl6%2FbmHKqCKN5plNvMBU40TXEDl15ZDIAzJw%2F9m8R1d8utQbzT9MrPFN&amp;TOPIC_ID=5853" target="_blank">
          PCOS Resources for a Healthier You
         </a>
         – From the Center for Young Women's Health of Boston Children's Hospital [
         <a href="#rid66">
          66
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpedsendo.org%2Fpatient-resource%2Fpolycystic-ovary-syndrome%2F&amp;token=WSSYIc3cOj5Gh5gQdKxkJrdBsHpn59ZFHX9DDqXTUOeW%2BTLd9MkC%2Fpu778upUvVlJVuIdyOhe1ff%2FQrHlW2e80ZQGJg5KM8ogyQyNM0S2FU%3D&amp;TOPIC_ID=5853" target="_blank">
          Polycystic Ovary Syndrome: A Guide for Families
         </a>
         – From the Pediatric Endocrine Society and the American Academy of Pediatrics [
         <a href="#rid67">
          67
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.monash.edu%2F__data%2Fassets%2Fpdf_file%2F0005%2F1429772%2FASK-PCOS-Evidence-based-information-for-women-with-Polycystic-ovary-syndrome.pdf&amp;token=BoYxw0DYTy1AzdxEqo8pXGus8UTX447ehrhy01qmVgZ5ALKg%2BU18jnw330leR6wdoMHZflLF%2BVeNc0mXvaPpc5WkzWq%2FJAIeV1mms2j0Ck%2FczJWMMCdxwSFOKR6927%2BKhuGQCwKhOPD7aXqd2f9ONqOJdAPpDxilxlI0IG6niKwixWJDewSUqOf7myVU8TvR&amp;TOPIC_ID=5853" target="_blank">
          ASK PCOS
         </a>
         – Evidence-based information for women with PCOS (website and app) [
         <a href="#rid68">
          68
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2220925910">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110097.html" rel="external">
          "Society guideline links: Polycystic ovary syndrome"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/110632.html" rel="external">
          "Society guideline links: Hirsutism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1183033">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15605.html" rel="external">
          "Patient education: Polycystic ovary syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/2163.html" rel="external">
          "Patient education: Polycystic ovary syndrome (PCOS) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Several treatment options are available for adolescents with polycystic ovary syndrome (PCOS)  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ). The choice of therapy depends on the individual adolescent's symptoms, goal for treatment, and preferences (eg, cost).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of abnormal uterine bleeding with or without hirsutism
         </strong>
         –
         <strong>
         </strong>
         In adolescents who experience the menstrual and/or cutaneous symptoms of PCOS, we suggest the use of estrogen-progestin combination oral contraceptives (COCs) as first-line treatment rather than other therapies  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oligo-amenorrhea with hirsutism
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients without a contraindication to estrogen – We prescribe a combined estrogen-progestin contraceptive.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients with a contraindication to estrogen – We prescribe a progestin-only contraceptive with an antiandrogen  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ); among antiandrogens, we suggest
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         rather than other antiandrogens (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         (See
         <a class="local">
          'Oligo-amenorrhea with hirsutism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oligo-amenorrhea without hirsutism
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients interested in contraception without an estrogen contraindication – We prescribe a COC  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients interested in contraception with an estrogen contraindication – We prescribe a progestin-only contraceptive  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients not interested in contraception – We prescribe cyclic progestin or a cyclic combined estrogen-progestin contraceptive (the latter is not an option if there is an estrogen contraindication).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         (See
         <a class="local">
          'Oligo-amenorrhea without hirsutism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Excessive bleeding with hirsutism
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients without a contraindication to estrogen – We prescribe a combined estrogen-progestin contraceptive  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ). If the bleeding puts the patient at risk for anemia, higher doses of estrogen are sometimes needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients with a contraindication to estrogen – We prescribe a progestin-only contraceptive with an antiandrogen (typically
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         as above)  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         (See
         <a class="local">
          'Excessive bleeding with hirsutism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Excessive bleeding without hirsutism
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients without a contraindication to estrogen – We prescribe a combined estrogen-progestin contraceptive  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ). If the bleeding puts the patient at risk for anemia, higher doses of estrogen are sometimes needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients with a contraindication to estrogen – We prescribe a progestin-only contraceptive  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         (See
         <a class="local">
          'Excessive bleeding without hirsutism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of hirsutism without abnormal uterine bleeding
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients without a contraindication to estrogen – We prescribe a combined estrogen-progestin contraceptive  (
         <a class="graphic graphic_table graphicRef110726" href="/z/d/graphic/110726.html" rel="external">
          table 1
         </a>
         ). The effects of hormone treatments on hirsutism are maximal after 9 to 12 months of therapy. If the response to a combined hormonal method is not adequate, we add an antiandrogen (
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         as above).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with a contraindication to estrogen – We prescribe a progestin-only contraceptive with an antiandrogen (
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         as above)  (
         <a class="graphic graphic_table graphicRef67829" href="/z/d/graphic/67829.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         (See
         <a class="local">
          'Hirsutism without abnormal uterine bleeding'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of obesity and impaired glucose tolerance
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Weight loss improves menstrual regularity, acanthosis nigricans, and hyperandrogenemia. Lifestyle recommendations (eg, exercise and diet) are the same as in patients without PCOS.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients for whom weight loss does not occur despite lifestyle recommendations, we test for impaired glucose tolerance. If impaired glucose tolerance is diagnosed (hemoglobin A1c result of 5.7 to 6.5 percent or a two-hour blood glucose result of 140 to 199 mg/dL on an oral glucose tolerance test), we suggest treatment with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Treatment of obesity and insulin resistance'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rosenfield RL. The Diagnosis of Polycystic Ovary Syndrome in Adolescents. Pediatrics 2015; 136:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu T, Goodarzi MO. Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization. J Clin Endocrinol Metab 2022; 107:e899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCartney CR, Marshall JC. CLINICAL PRACTICE. Polycystic Ovary Syndrome. N Engl J Med 2016; 375:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twig G, Yaniv G, Levine H, et al. Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood. N Engl J Med 2016; 374:2430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berni TR, Morgan CL, Rees DA. Women With Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: a Population Study. J Clin Endocrinol Metab 2021; 106:e3369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen H, Zhang Y, Li S, et al. The Genetic Association of Polycystic Ovary Syndrome and the Risk of Endometrial Cancer: A Mendelian Randomization Study. Front Endocrinol (Lausanne) 2021; 12:756137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazelwood E, Sanderson E, Tan VY, et al. Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis. BMC Med 2022; 20:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98:4565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2023; 108:2447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibáñez L, Oberfield SE, Witchel S, et al. An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. Horm Res Paediatr 2017; 88:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018; 110:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peña AS, Witchel SF, Hoeger KM, et al. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med 2020; 18:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfield RL. Perspectives on the International Recommendations for the Diagnosis and Treatment of Polycystic Ovary Syndrome in Adolescence. J Pediatr Adolesc Gynecol 2020; 33:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witchel SF, Oberfield S, Rosenfield RL, et al. The Diagnosis of Polycystic Ovary Syndrome during Adolescence. Horm Res Paediatr 2015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril 2023; 120:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Screening and Management of the Hyperandrogenic Adolescent: ACOG Committee Opinion, Number 789. Obstet Gynecol 2019; 134:e106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haamid F, Sass AE, Dietrich JE. Heavy Menstrual Bleeding in Adolescents. J Pediatr Adolesc Gynecol 2017; 30:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Mendonça-Louzeiro MR, Annichino-Bizzacchi JM, Benetti-Pinto CL. Android fat distribution affects some hemostatic parameters in women with polycystic ovary syndrome compared with healthy control subjects matched for age and body mass index. Fertil Steril 2015; 104:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vu LT, Nobuhara KK, Lee H, Farmer DL. Determination of risk factors for deep venous thrombosis in hospitalized children. J Pediatr Surg 2008; 43:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nightingale AL, Lawrenson RA, Simpson EL, et al. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000; 5:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishola T, Kirk SE, Guffey D, et al. Risk factors and co-morbidities in adolescent thromboembolism are different than those in younger children. Thromb Res 2016; 141:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajpurkar M, Biss T, Amankwah EK, et al. Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. A systematic review. Thromb Haemost 2017; 117:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Georgopoulos G, Hotchkiss MS, McNair B, et al. Incidence of Deep Vein Thrombosis and Pulmonary Embolism in the Elective Pediatric Orthopaedic Patient. J Pediatr Orthop 2016; 36:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pastor CL, Griffin-Korf ML, Aloi JA, et al. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 1998; 83:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eagleson CA, Gingrich MB, Pastor CL, et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000; 85:4047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Styne DM, Arslanian SA, Connor EL, et al. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017; 102:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cremer M, Phan-Weston S, Jacobs A. Recent innovations in oral contraception. Semin Reprod Med 2010; 28:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon CM, Pitts SA. Approach to the adolescent requesting contraception. J Clin Endocrinol Metab 2012; 97:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaenglein AL. Acne Vulgaris. N Engl J Med 2018; 379:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legro RS, Pauli JG, Kunselman AR, et al. Effects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab 2008; 93:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swiglo BA, Cosma M, Flynn DN, et al. Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008; 93:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrionuevo P, Nabhan M, Altayar O, et al. Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis. J Clin Endocrinol Metab 2018; 103:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields A, Flood K, Barbieri JS. Spironolactone use for acne is not associated with an increased risk of venous thromboembolism: A matched, retrospective cohort study. J Am Acad Dermatol 2023; 88:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manso G, Thole Z, Salgueiro E, et al. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiol Drug Saf 2006; 15:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinemann LA, Will-Shahab L, van Kesteren P, et al. Safety of cyproterone acetate: report of active surveillance. Pharmacoepidemiol Drug Saf 1997; 6:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domecq JP, Prutsky G, Mullan RJ, et al. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab 2013; 98:4646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Zegher F, Ibáñez L. Therapy: Low-dose flutamide for hirsutism: into the limelight, at last. Nat Rev Endocrinol 2010; 6:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moretti C, Guccione L, Di Giacinto P, et al. Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial. J Clin Endocrinol Metab 2018; 103:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koukourakis MI, Kakouratos C, Kalamida D, et al. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines. Anticancer Drugs 2018; 29:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ladson G, Dodson WC, Sweet SD, et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril 2011; 95:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2006; 160:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz SL, Wu JF, Berner B. Metformin extended release for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2006; 7:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murthy AS. Obesity and contraception: emerging issues. Semin Reprod Med 2010; 28:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro J. Clinical practice. Hair loss in women. N Engl J Med 2007; 357:1620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoeger K, Davidson K, Kochman L, et al. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008; 93:4299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2011; 24:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong JM, Gallagher M, Gooding H, et al. A randomized pilot study of dietary treatments for polycystic ovary syndrome in adolescents. Pediatr Obes 2016; 11:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardner CD, Trepanowski JF, Del Gobbo LC, et al. Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial. JAMA 2018; 319:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong SC, Bolling CF, Michalsky MP, et al. Pediatric Metabolic and Bariatric Surgery: Evidence, Barriers, and Best Practices. Pediatrics 2019; 144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fruzzetti F, Perini D, Russo M, et al. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol 2017; 33:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al Khalifah RA, Florez ID, Dennis B, et al. Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis. Pediatrics 2016; 137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrannini E. The target of metformin in type 2 diabetes. N Engl J Med 2014; 371:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pernicova I, Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017; 60:1577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Day EA, Ford RJ, Smith BK, et al. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat Metab 2019; 1:1202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. Endocr Rev 2021; 42:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harborne L, Fleming R, Lyall H, et al. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003; 361:1894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; :CD003053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbieri RL. Metformin for the treatment of polycystic ovary syndrome. Obstet Gynecol 2003; 101:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrmann DA, Cavaghan MK, Imperial J, et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002; 87:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007; 11:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiNicolantonio JJ, H O'Keefe J. Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. Open Heart 2022; 9.
          </a>
         </li>
         <li class="breakAll">
          Center for Young Women's Health. PCOS (polycystic ovary syndrome). Available at: https://youngwomenshealth.org/2014/02/25/polycystic-ovary-syndrome/ (Accessed on March 15, 2018).
         </li>
         <li class="breakAll">
          Pediatric Endocrine Society and the American Academy of Pediatrics: Polycystic Ovary Syndrome: A guide for Patients and
Parents. Available at: https://www.pedsendo.org/assets/patients_families/Educational_Materials/PolycysticOvarySyndrome.pdf (Accessed on March 15, 2018).
         </li>
         <li class="breakAll">
          ASK PCOS: Evidence-based information for women with PCOS. Monash University on behalf of the National Health and Medical Research Council, Centre for Research Excellence in PCOS, and the Australian PCOS Alliance 2018. Available at: https://www.monash.edu/__data/assets/pdf_file/0005/1429772/ASK-PCOS-Evidence-based-information-for-women-with-Polycystic-ovary-syndrome.pdf.
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5853 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26598450" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The Diagnosis of Polycystic Ovary Syndrome in Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34669940" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27406348" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : CLINICAL PRACTICE. Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27074389" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34061968" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Women With Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: a Population Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34803918" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The Genetic Association of Polycystic Ovary Syndrome and the Risk of Endometrial Cancer: A Mendelian Randomization Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35436960" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24151290" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37580314" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29156452" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30033227" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32204714" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Adolescent polycystic ovary syndrome according to the international evidence-based guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32615268" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Perspectives on the International Recommendations for the Diagnosis and Treatment of Polycystic Ovary Syndrome in Adolescence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25833060" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The Diagnosis of Polycystic Ovary Syndrome during Adolescence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37589624" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29522147" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31568365" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Screening and Management of the Hyperandrogenic Adolescent: ACOG Committee Opinion, Number 789.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28108214" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Heavy Menstrual Bleeding in Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26051101" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Android fat distribution affects some hemostatic parameters in women with polycystic ovary syndrome compared with healthy control subjects matched for age and body mass index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18558189" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Determination of risk factors for deep venous thrombosis in hospitalized children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11245554" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27060749" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Risk factors and co-morbidities in adolescent thromboembolism are different than those in younger children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28331932" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25575361" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Incidence of Deep Vein Thrombosis and Pulmonary Embolism in the Elective Pediatric Orthopaedic Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9467578" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11095431" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28359099" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20391327" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Recent innovations in oral contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22223764" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Approach to the adolescent requesting contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30281982" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Acne Vulgaris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18056769" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Effects of continuous versus cyclical oral contraception: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18252786" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29522176" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36842507" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Spironolactone use for acne is not associated with an increased risk of venous thromboembolism: A matched, retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16294367" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15073785" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Safety of cyproterone acetate: report of active surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24092830" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20657543" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Therapy: Low-dose flutamide for hirsutism: into the limelight, at last.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29211888" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29381490" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21193187" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16520442" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16556094" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Metformin extended release for the treatment of type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20352564" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Obesity and contraception: emerging issues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17942874" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Clinical practice. Hair loss in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18728175" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21419674" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26132306" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A randomized pilot study of dietary treatments for polycystic ovary syndrome in adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29466592" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31656225" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Pediatric Metabolic and Bariatric Surgery: Evidence, Barriers, and Best Practices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27808588" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27244814" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25317875" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The target of metformin in type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24393785" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Metformin--mode of action and clinical implications for diabetes and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28776086" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The mechanisms of action of metformin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32694673" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32897388" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Cellular and Molecular Mechanisms of Metformin Action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12788588" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12917943" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12681887" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Metformin for the treatment of polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9024248" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11836287" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10634377" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18074942" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35236761" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
